Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report)'s share price traded up 2.4% on Thursday . The stock traded as high as $5.30 and last traded at $5.30. 966 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 9,819 shares. The stock had previously closed at $5.18.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $25.00 price objective on shares of Genenta Science in a research report on Wednesday, October 2nd.
View Our Latest Stock Report on GNTA
Genenta Science Stock Performance
The company's 50-day moving average price is $5.22 and its 200-day moving average price is $4.30.
Institutional Investors Weigh In On Genenta Science
An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science as of its most recent filing with the SEC. Institutional investors own 15.13% of the company's stock.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Recommended Stories
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
